You are here

  • Home
  • Archive
  • Volume 78, Issue 5
  • Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Article info

Article menu
Download PDFPDF
Sjögren’s syndrome
Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity

Authors

  1. Correspondence to Dr Stephen John Oliver, Translational Medicine, Novartis Pharma, Basel 4002, Switzerland; stephen.oliver{at}novartis.com
View Full Text

Citation

Dörner T, Posch MG, Li Y, et al
Treatment of primary Sjögren’s syndrome with ianalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity
Annals of the Rheumatic Diseases 2019;78:641-647.

Publication history

  • Received November 10, 2018
  • Revised January 21, 2019
  • Accepted February 14, 2019
  • First published March 2, 2019.
Online issue publication 
April 12, 2019

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.